Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2019-03-29 Annual Report
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
glpg_jv18_29 maart 2019.pdf
Annual Report Classification · 100% confidence The document is titled 'Jaarverslag 2018' (Annual Report 2018) for the Galapagos group. It contains a comprehensive overview of the company's strategy, R&D pipeline, risk factors, CSR report, corporate governance, and detailed financial statements (Jaarrekening) including consolidated and statutory results. Given the length and the inclusion of full financial reporting for the fiscal year, it is classified as an Annual Report (10-K). FY 2018
2019-03-29 Dutch
GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY ENDPOINT IN THE PHASE 3 FINCH 3 STUDY IN METHOTREXATE-NAÏVE RHEUMATOID ARTHRITIS PATIENTS
Earnings Release Classification · 95% confidence The document is a press release dated March 28, 2019, announcing positive Phase 3 trial results (FINCH 3 study) for the drug filgotinib in rheumatoid arthritis patients. It details efficacy data (ACR scores, remission rates) and safety/tolerability information. This format—a formal announcement of clinical trial results, often including tables and quotes from management, released to the public and regulatory bodies—is characteristic of an Earnings Release (ER) or a general announcement. Since it is a detailed announcement of clinical trial results rather than a full, comprehensive periodic financial report (like a 10-K or IR), and it is not a transcript (CT) or a presentation (IP), the most fitting category is Earnings Release (ER), as these announcements often accompany or precede quarterly financial reporting periods, even if the primary focus here is clinical data. Given the context of a major clinical update, ER is the best fit among the options provided for a significant, time-sensitive corporate announcement of performance/data milestones. Q1 2019
2019-03-29 Dutch
GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY ENDPOINT IN THE PHASE 3 FINCH 3 STUDY IN METHOTREXATE-NAÏVE RHEUMATOID ARTHRITIS PATIENTS
Regulatory Filings Classification · 99% confidence The document is a press release dated March 28, 2019, announcing positive Phase 3 clinical trial results (FINCH 3) for the drug filgotinib in rheumatoid arthritis patients. It details efficacy endpoints (ACR20/50/70), safety profiles, and includes quotes from management. This format—a formal announcement of clinical trial data and key results—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/product news. Since it focuses on the immediate release of key data points rather than a comprehensive periodic financial report (like 10-K or IR), 'ER' (Earnings Release) is the closest fit among the options for a major, time-sensitive announcement, although it is technically a clinical trial update press release. Given the options, 'ER' captures the nature of a time-sensitive, high-impact announcement of results. It is not a transcript (CT), a formal annual report (10-K), or a presentation (IP). It is a direct announcement of results, not just an announcement that a report is forthcoming (RPA).
2019-03-29 English
GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA)
Earnings Release Classification · 95% confidence The document is a press release dated March 28, 2019, issued by Gilead Sciences and Galapagos NV. The content focuses on announcing and summarizing interim safety data from ongoing Phase 3 clinical trials (FINCH program) and long-term data from a Phase 2b study (DARWIN 3) for the drug candidate filgotinib in rheumatoid arthritis. This type of announcement, which releases key clinical trial results and safety data to the public and investors, is characteristic of an Earnings Release (ER) or a general announcement related to clinical progress. Since it is a formal announcement of periodic results (even if not strictly quarterly earnings, it is a periodic update on a key development program), and it contains detailed data tables and management commentary, it aligns best with the 'Earnings Release' (ER) category, which covers initial announcements of periodical financial/operational results. It is not a full Annual Report (10-K), a formal Audit Report (AR), or a transcript (CT). It is a direct release of operational/clinical results. Q1 2019
2019-03-29 Dutch
GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA)
Earnings Release Classification · 95% confidence The document is a press release dated March 28, 2019, announcing updated safety information for the investigational compound filgotinib from Phase 3 FINCH trials and Phase 2b DARWIN 3 data. It contains detailed tables summarizing adverse events and includes forward-looking statements referencing Gilead's Annual Report on Form 10-K. The content is a summary of clinical trial results and safety data, which is characteristic of an Earnings Release (ER) or a general announcement related to clinical progress. Since it is a detailed announcement of results (not just a brief notification of a report release), and it focuses on financial/operational results (clinical trial outcomes impacting future revenue/risk), it aligns best with an Earnings Release (ER) or potentially an Investor Presentation (IP) if it were structured as slides. Given the format as a press release detailing interim results and safety profiles, ER is the most appropriate fit among the options, as these often accompany or precede formal earnings reports, or serve as major operational updates. It is not a full 10-K, AR, or a simple RPA. Q1 2019
2019-03-29 English
20-F Filing
Annual Report FY 2018
2019-03-29 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.